Kadmon consultant charged with insider trading ahead of biotech’s $1.9B sale to Sanofi: SEC – FiercePharma
For one financial advisor, the urge to profit off Sanofi’s $1.9 billion Kadmon buyout allegedly proved too powerful to resist. | The Securities and Exchange Commission has charged California-based executive compensation consultant Frank Glassner with insider …